
THE EXCITING JOURNEY FROM FLU VIRUS TO VACCINE

SURVEILLANCE ACTIVITIES BEFORE MANUFACTURING




ONCE THESE 6 CENTERS RECEIVE THE VIRUS STRAINS, THEY RUN ADVANCED ANTIGENIC AND GENETIC ANALYSES

THE COLLABORATING CENTERS MONITOR CHANGES IN THE STRAINS AND DETERMINE THE COMPOSITION OF THE NEW VACCINE. THEY THEN SHIP THE VIRUSES TO SPEACIALIZED LABS TO DEVELOP A SPECIAL FORM OF VIRUSES FOR THE VACCINE PRODUCTION

OTHER VIRUS OF PANDEMIC POTENTIAL

THE WHO SCIENTIFIC COMMITTEE FOR INFLUENZA VACCINE COMPOSITION MEETS TWICE PER YEAR TO DECIDE WHICH VIRUS STRAINS SHOULD GO INTO VACCINE MANUFACTURING

GENEVA



HIGH PRIORITY GROUPS FOR FLU VACCINATION: CHILDREN AGED 6-59 MONTHS - PREGNANT WOMEN - ELDERLY - HEALTH-CARE WORKERS -INDIVIDUALS WITH SPECIFIC CHRONIC MEDICAL CONDITIONS THE CONCERTED YEAR-ROUND EFFORT BY THOU-SANDS OF HEALTHCARE PROFESSIONALS, SCI-ENTISTS, AND VACCINE MANUFACTURERS WORLD-WIDE IS A VITAL STEP IN DEVELOPING THE FLU VACCINE

HTTP://WWW.JFPMA.ORG/RESOURCE-CENTRE/THE-EXCITING-JOURNEY-FROM-FLU-VIRUS-TO-VACCINE/ EVERY YEAR, THE SELECTED VIRUSES ARE SHIPPED TO MANUFACTURERS WORLDWIDE TO START THE VACCINE PRODUCTION, IN BIG QUANTITIES, HIGH QUALITY, AND WITHIN SPECIFIC TIMELINES'

International Federation
of Pharmaceutical
Manufacturers & Associations

